Form 8-K - Current report:
SEC Accession No. 0001193125-25-137432
Filing Date
2025-06-09
Accepted
2025-06-09 07:28:48
Documents
14
Period of Report
2025-06-09
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d74901d8k.htm   iXBRL 8-K 37263
2 EX-99.1 d74901dex991.htm EX-99.1 21648
  Complete submission text file 0001193125-25-137432.txt   219569

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA nams-20250609.xsd EX-101.SCH 3567
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE nams-20250609_def.xml EX-101.DEF 13771
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE nams-20250609_lab.xml EX-101.LAB 22355
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nams-20250609_pre.xml EX-101.PRE 14559
16 EXTRACTED XBRL INSTANCE DOCUMENT d74901d8k_htm.xml XML 5727
Mailing Address GOOIMEER 2-35 NARRDEN P7 1411 DC
Business Address GOOIMEER 2-35 NARRDEN P7 1411 DC 35 206 2971
NewAmsterdam Pharma Co N.V. (Filer) CIK: 0001936258 (see all company filings)

EIN.: 000000000 | State of Incorp.: P7 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41562 | Film No.: 251032836
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)